Literature DB >> 8114918

Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice.

S M Toggas1, E Masliah, E M Rockenstein, G F Rall, C R Abraham, L Mucke.   

Abstract

Many people infected with human immunodeficiency virus type 1 (HIV-1) develop neurological complications that can culminate in dementia and paralysis. The discrepancy between the severity of impairment and the paucity of detectable HIV-1 within neurons has led to an intense search for diffusible virus- and host-derived factors that might be neurotoxic (see ref. 2 for review). The HIV-1 envelope glycoprotein gp120 is an extracellular protein that is shed from infected cells and so has the potential to diffuse and interact with distant uninfected brain cells. Studies on cultured immature cells suggest that gp120 induces neurotoxicity (reviewed in refs 2, 4), and systemic injection of gp120 in neonatal rats and intracerebroventricular injection in adult rats results in deleterious effects on the brain. To assess the pathogenic potential of gp120 in the intact brain, we have now produced gp120 in the brains of transgenic mice and found a spectrum of neuronal and glial changes resembling abnormalities in brains of HIV-1-infected humans. The severity of damage correlated positively with the brain level of gp120 expression. These results provide in vivo evidence that gp120 plays a key part in HIV-1-associated nervous system impairment. This model should facilitate the evaluation and development of therapeutic strategies aimed at HIV-brain interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114918     DOI: 10.1038/367188a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  250 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

Review 2.  In vitro and animal models of human immunodeficiency virus infection of the central nervous system.

Authors:  Chadd E Nesbit; Stanley A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 3.  Humanized mouse models for HIV-1 infection of the CNS.

Authors:  Jenna B Honeycutt; Patricia A Sheridan; Glenn K Matsushima; J Victor Garcia
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

Review 4.  Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Authors:  Ricky Maung; Kathryn E Medders; Natalia E Sejbuk; Maya K Desai; Rossella Russo; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

Review 5.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

6.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

7.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

8.  Interferon-stimulated gene 15 as a general marker for acute and chronic neuronal injuries.

Authors:  Ren-Gang Wang; Marcus Kaul; Dong-Xian Zhang
Journal:  Sheng Li Xue Bao       Date:  2012-10-25

9.  Neuronal expression of human immunodeficiency virus type 1 env proteins in transgenic mice: distribution in the central nervous system and pathological alterations.

Authors:  F Berrada; D Ma; J Michaud; G Doucet; L Giroux; A Kessous-Elbaz
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  HIV-gp120 and physical dependence to buprenorphine.

Authors:  J Palma; M E Abood; K Benamar
Journal:  Drug Alcohol Depend       Date:  2015-02-26       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.